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Abstract
Background: Infection is a common complication seen in ICU patients. Given the correlation between infection
and mortality in these patients, a rapid etiological diagnosis and the determination of antimicrobial resistance
markers are of paramount importance, especially in view of today’s globally spread of multi drug resistance
microorganisms. This paper reviews some of the rapid diagnostic techniques available for ICU patients with
infections.
Methods: A narrative review of recent peer-reviewed literature (published between 1995 and 2014) was performed
using as the search terms: Intensive care medicine, Microbiological techniques, Clinical laboratory techniques,
Diagnosis, and Rapid diagnosis, with no language restrictions.
Results: The most developed microbiology fields for a rapid diagnosis of infection in critically ill patients are those
related to the diagnosis of bloodstream infection, pneumonia –both ventilator associated and non-ventilator
associated–, urinary tract infection, skin and soft tissue infections, viral infections and tuberculosis.
Conclusions: New developments in the field of microbiology have served to shorten turnaround times and
optimize the treatment of many types of infection. Although there are still some unresolved limitations of the use
of molecular techniques for a rapid diagnosis of infection in the ICU patient, this approach holds much promise for
the future.
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Background
Although intensive care units (ICUs) have fewer than
ten percent of the total number of beds in most hospi-
tals, more than 20 percent of all nosocomial infections
are acquired in ICUs and carry substantial morbidity,
mortality, and expense [1-4]. The most common clinically
significant infections observed in the ICU are intravascular
catheter-related bloodstream infection (CR-BSI), ventilator
associated pneumonia (VAP), and catheter associated
urinary tract infection (CA-UTI).
In addition, multidrug-resistant (MDR) pathogens are
evermore frequently isolated in ICUs [5,6] and this hinders
the initiation of appropriate, effective antibiotic therapy,
which correlates with excess mortality [7-9].
In this setting, a rapid etiologic microbiological diag-
nosis is mandatory. This paper reviews some of the rapid
diagnostic techniques available for ICU patients with
infections.
Main text
Rapid diagnosis of catheter-related bloodstream
infections (CR-BSI)
A diagnosis of CR-BSI should be based on microbio-
logical identification of the catheter as the source of
bloodstream infection, and may be performed with or
without catheter removal [10].
Attempts to establish the role of the catheter in epi-
sodes of BSI are justified by the following: a high propor-
tion of the suspicious of CR-BSI are note confirmed
after catheter removal and culture [11], and many CR-BSI
can be managed empirically without immediately remov-
ing the catheter [12-14]. Central venous catheter (CVC)
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removal limits vascular access, and diagnostic methods
exist that do not require catheter removal [15].
Rapid procedures that do not require catheter removal
The conservative approach to CR-BSI diagnosis (i.e.,
without catheter withdrawal) is highly convenient. Con-
servative procedures include differential paired quantita-
tive blood cultures (comparison of colony counts in
peripheral vein blood versus catheter hubs), superficial
cultures (semiquantitative cultures of skin around the
portal of entry and of catheter hubs), and a method
comparing time to positivity between concurrent blood
cultures of peripheral vein and catheter hub samples,
named “differential time to positivity” (DTTP) [16-18].
Paired central/peripheral cultures
A ratio or differential colony count ≥3:1 cfu/mL of bac-
teria from the catheter-drawn blood cultures compared to
percutaneously-drawn blood cultures is usually accepted
as a prove of CR-BSI. This cutoff shows a sensitivity (Se)
of around 80% and specificity (Sp) of 90-100% [19].
Blood should be drawn from all hubs, representing the
different catheter lumens [20]. This technique is usually
performed with lysis-centrifugation tubes. Blood is inoc-
ulated in tubes containing the cell-lysing agent saponin,
followed by vortexing and centrifugation. Then, after re-
moving the supernatant (lysate), the concentrate is
plated on agar medium and the plates incubated over-
night before counting. The tubes need to be processed
within 8 hours of inoculation [21]. Drawbacks of this
technique include: the manual and individual processing
of each individual sample, the risk of contamination, the
risk of exposure of laboratory technicians to blood and
the high cost [19].
Differential time to positivity (DTTP)
DTTP supporting CRBSI diagnosis is defined as a differ-
ence in time to positivity of ≥2 h between a CVC blood
culture and a peripheral blood culture, or between 2
CVC blood cultures from different lumens of a multi-
lumen catheter [10,22,23]. The DTTP test is conducted
using a continuous-monitoring automated blood culture
system. This method requires inoculating the same
amount of blood in each culture bottle. For multiple
lumen catheters, blood should be drawn from all ports
[20,24]. To ensure accurate results, the first milliliters of
blood drawn from the catheter should be used for cul-
ture. Then, bottles must be sent to the laboratory and
incubated as soon as they arrive there. Depending on
the type of catheter (short- vs. long-term) and the pa-
tient, the test shows a Se of 86-93%, Sp of 87-92%, posi-
tive predictive value (PPV) of 85-88% and negative
predictive value (NPV) of 89-95% [22,24,25].
DTTP is nowadays the main technique to assess CR-BSI
used in most microbiology departments. Caution in inter-
pretation should be applied in patients receiving anti-
microbial agents [22]. The validity of DTT, however, has
been recently questioned by Kaasch et al. [26]., that found
a poor diagnostic performance (Se 37%, Sp 77%, PPV 46%,
NPV 70%, validity 63%) in patients with CR-BSI caused by
Staphylococcus aureus. However, they failed to adhere to
instructions of utmost importance related to the protocol.
The microbiology service was not available on a 24/7
basis, suggesting long pre-incubation periods before intro-
ducing the bottles in the automated blood culture machine,
possibly leveling times to positivity of paired cultures, thus
invalidating the diagnostic procedure [27,28].
Our group recently demonstrated that the DTTP
threshold applied to bacterial CR-BSI is not applicable in
cases of CR-BSI caused by Candida spp. [29].
Superficial cultures (combined exit-site and hub cultures)
We call “superficial cultures” to the combination of
semiquantitative cultures independently obtained from
the 2 cm of skin surrounding the catheter insertion site
and the various hubs.
The threshold for positivity of these semiquantative
cultures is 15 cfu per plate.
Growth of <15 cfus per plate of the same microbe
from both the insertion site culture and catheter hub/s
culture/s strongly suggests that the catheter is not the
source of the BSI. Superficial cultures are justified only
in cases of suspected CR-BSI (targeted cultures) in
which they serve to rule out CR-BSI owing to their high
sensitivity and good negative predictive value [16].
Gram staining of skin and hub swabs may also be
helpful for the rapid diagnosis of CR-BSI [30].
Recently Bouza et al. compared the use of paired
blood cultures, superficial cultures and DTTP for the
diagnosis of CR-BSI without catheter removal [31].
DTTP showed a better sensitivity and negative predictive
capacity than paired blood cultures to detect catheter tip
colonization (96.4% and 99.4% vs. 71.4% and 95.6%, re-
spectively) (Table 1). However, central/peripheral paired
blood cultures showing a ratio >5:1 provided the best
specificity (97.7%) for a diagnosis of CR-BSI. The three
tests showed a high negative predictive capacity. If a
negative result was obtained in any of the three tests, it
was possible to rule out catheter colonization and CR-BSI
reasonably well.
Rapid diagnosis of sepsis
The diagnosis of BSI among critically ill patients is a
major challenge. Blood cultures are still considered the
gold standard diagnostic procedure since pathogens may
be isolated and subjected to antibiotic susceptibility testing
(AST). In effect, the use of blood cultures in septic shock
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patients as part of the compliance with six or more inter-
ventions of the 6-hour resuscitation bundle of the “surviv-
ing sepsis campaign” has been related to a reduction in
mortality [32].
Blood cultures, however, are time-consuming and slow.
They only detect viable microorganisms and show a low
sensitivity for slow growing, intracellular and fastidious
microorganisms. Overall positivity may be as low as 30-
40% despite proper implementation of standard proce-
dures, adequate blood volume collection and a high clin-
ical suspicion of BSI.
Molecular techniques are ever-evolving to provide faster
and more sensitive results along with the direct identifica-
tion of responsible pathogens [33-36]. These techniques
are likely to impact soon clinical decision-making and
antibiotic treatment.
Existing commercial nucleic acid testing (NAT) diagnos-
tic tests are all based on a similar procedure: pathogen
lysis, nucleic acid extraction and purification, amplification
of nucleic acids by PCR, and identification by various
methods, such as ELISA-based hybridization, fluorescence-
based real-time detection, liquid or solid phase microarray
detection, sequencing and database recognition [34]. The
reader is referred to Afshari et al. [34] for a comprehensive
review of the tests commercially available today.
Pathogen-specific assays are even capable of detecting
genes encoding resistance to antibiotics, such as mecA
in staphylococci or van genes in enterococci.
A recent meta-analysis on the use of LightCycler
SeptiFast revealed a Se and Sp of 80% and 95%, respect-
ively, for this technique to detect bacteremia, and of 61%
and 99%, respectively, to detect fungemia [36]. However,
the bacteremia outcome subgroup showed high variation.
The turnaround time of the technique was 6 hours.
In general terms, there are still important shortcom-
ings of molecular techniques. For instance, the lack of
an appropriate gold standard since blood cultures are
unable to detect many true cases of infection; emphasis
on microbiological rather than clinical assessment; no
guidance for targeting appropriate clinical situations;
and the potential for wrong interpretation of results if
no expert assistance is available [37,38].
Ideally, tests should provide relevant information 2–6
hours after samples are taken on which to base the
choice of treatment. Under real-life conditions, there are
often considerable delays due to practical issues, such as
availability of staff outside daily routines or batch ana-
lysis of samples [39]. Test sensitivity needs to be im-
proved to detect clinically relevant low bacterial loads
and fastidious microorganisms. They should be able to
distinguish between living and dead bacteria, especially
for patients on antibiotics. They should also be able to
clarify the impact of DNAemia in cases of clinical signs
of BSI. For instance, in a recent paper on the combined
use of blood cultures and SeptiFast to predict compli-
cated BSI in cases of staphylococcal or Candida infec-
tion, the authors found that patients with a positive
SeptiFast result between days 3 and 7 after a positive
blood culture had an almost 8-fold-higher risk of devel-
oping a complicated bloodstream infection [40].
At present, molecular tests are used to complement
the results of traditional culture, especially in serious
clinical situations such as ICU patients with severe sepsis
[37]. They also have the potential to be a cost-effective
strategy to manage sepsis [41]. However, conventional
blood cultures remain necessary because of the high inci-
dence of multidrug-resistant bacteria in ICU patients and
the need for AST to establish adequate treatment.
Other helpful rapid tests for the diagnosis of sepsis
Matrix assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry (MS) serves to iden-
tify isolated colonies of bacteria and fungi, and can also
be used directly on positive blood culture broths in
under one hour after the technician has been alerted of
growth. This procedure is now replacing biochemical
and gene sequencing methods for organism identifica-
tion because it is easily implemented, highly accurate, in-
expensive and fast [42-44]. Some 5 to 10 ml of broth
from a single positive blood culture bottle are needed
for this technique. However, in most reports to date,
identification yields are greater for Gram negative organ-
isms than Gram positives or yeasts. To improve diagnosis,
different sample preparation methods for positive blood








Sensitivity 78.6 (59.0-91.7) 71.4 (51.3-86.8) 96.4 (81.7-99.9)
Specificity 92.0 (87.0-95.6) 97.7 (94.3-99.4) 90.3 (85.0-94.3)
Positive predictive value 61.1 (43.5-76.9) 83.3 (62.6-95.3) 61.4 (45.5-75.6)
Negative predictive value 96.4 (92.4-98.7) 95.6 (91.4-98.1) 99.4 (96.6-99.9)
Accuracy 90.2 (85.3-93.9) 94.1 (90.0-96.9) 91.2 (86.4-94.7)
From reference [31].
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cultures have been tested. Most of these methods include
preincubation with different detergent concentrations (e.g.,
5% saponin, 5% sodium dodecyl sulfate –SDS-, 0.1%
Tween 80) or use of the Sepsityper kit (Bruker Daltonik
GmbH, Bremen, Germany) [45,46].
In a recent study conducted at our center, we assessed
the use of MALDI-TOF MS as a routine method for the
identification of microorganisms directly from positive
blood culture bottles (BCB) [47]. The turnaround time
for results ranged from 20 to 30 minutes, similar to that
reported in other studies. Analysis by bacteremia episode
led to the complete identification of 814 out of 1000 epi-
sodes (81.4%). As expected, Gram negative microorgan-
isms were better identified than Gram positives or
yeasts. However, by comparing spectral peaks we were
able to differentiate between Streptococcus pneumoniae
and Streptococcus mitis or Streptococcus oralis.
MALDI-TOF MS identification is available for clini-
cians within hours of a working shift, as opposed to 18 h
for a conventional identification method. Moreover, al-
though further improvement of sample preparation for
polymicrobial BCBs is required, the identification of
more than one pathogen in the same BCB provides a
valuable indication of unexpected pathogens when their
presence may remain undetected by Gram staining.
It has already proved useful for improving the ad-
equacy of antibiotic treatment of bacteremia [48].
Diagnostic and prognostic biomarkers in sepsis
More than 180 molecules have been described as po-
tential biological makers of sepsis. These molecules
include C-reactive protein (CRP), procalcitonin (PCT),
several cytokines, and cell surface markers [49], though
only 20% have been assessed for use in the diagnosis of
sepsis [50].
C-reactive protein was first described in the early 1930s.
This acute phase protein is released by the liver in re-
sponse to inflammation or tissue insult and is widely used
as a highly nonspecific marker of sepsis. In a study by
Póvoa et al. performed in 112 ICU patients, a serum CRP
>8.7 mg/dl showed a Se of 93% and Sp of 86% to detect
the presence of infection. Adding a temperature >38.2°C
to this threshold increased Sp to 100% [51].
The latter authors also observed that CRP concentra-
tions increased over time in patients with infection, yet
remained unchanged in non-infected patients. A daily
CRP variation of at least 4.1 mg/dl was predictive of
nosocomial infection with a Se of 92% and Sp of 71%;
when combined with a serum CRP above 8.7 mg/dl,
these values increased to 92 and 82%, respectively [52].
Similarly, in patients with CRP concentrations >10 mg/dl
on ICU admission, a decrease in CRP after 48 h was linked
to a mortality rate of 15%, while its increase was associated
with a mortality rate of 61% (p < 0.05) [53].
The peptide procalcitonin is synthesized by monocytes
that are in the process of adhesion. PCT levels rise when
there is local or systemic bacterial infection but not in
the presence of a virus or autoimmune disease. Thus,
PCT is more specific than CRP for detecting bacterial
infection.
In a recent prospective study, on day 1 after admission
to a medical-surgical ICU, a cut-off PCT >1.39 ng/ml
showed the best area under the curve (AUC) for diag-
nosing sepsis (87%) and levels were found to signifi-
cantly drop from day 1 to day 2 in survivors [54]. In
addition, high PCT levels have been linked to an in-
creased risk of mortality. As an example, in a recent pro-
spective multicentre observational study performed in
1156 Greek in-patients, a PCT > 0.85 ng/ml was associ-
ated with 45% mortality in ICU patients [55]. It would
appear that as for CRP, trends in PCT observed over
time are more useful than single measurements [56].
However, we have yet to find a marker specific enough
to provide a true diagnosis of BSI. The Surviving Sepsis
Campaign 2012 guidelines state that the utility of PCT
levels or other biomarkers to differentiate acute inflam-
matory patterns of sepsis from other causes of general-
ized inflammation (e.g., postoperative, other forms of
shock) remains to be demonstrated [57].
Rapid diagnosis of ventilator-associated pneumonia
Hospital-acquired pneumonia (HAP), especially ventilator-
associated pneumonia (VAP), is one of the leading causes
of infection and death in the ICU [58-62]. The incorrect
or delayed treatment of HAP within a few hours gives rise
to a worse prognosis and a higher mortality rate [63-65].
Useless antibiotics are also a cause of adverse events and
unnecessary expense [66]. Thus, the etiologic diagnosis of
VAP is a microbiological emergency because of its impact
on the morbidity and mortality of this disease.
Bacterial identification and AST take 2 or 4 days, so
there is a need for rapid diagnostic procedures. Rapid in-
formation is clearly more beneficial to the patient than
more complete but delayed information. Gram staining,
quantifying microorganisms in polymorphonuclear cells in
bronchoalveolar lavage samples, and antibiograms con-
ducted directly on clinical samples may provide informa-
tion that correlates with subsequent culture results.
New diagnostic techniques, such as real-time PCR as-
says and “in situ” hybridization of bacteria, have been
developed to speed up the identification of the patho-
gens responsible for this disease [67,68].
Lower respiratory tract samples for microbiology
All patients suspected of having VAP should undergo
lower respiratory tract (LRT) sampling followed by a mi-
croscopy examination and culture of the specimen [69].
Deciding upon the best type of sample for diagnosing
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VAP is controversial and at present no sampling proced-
ure has proved meaningfully superior to the rest [70-72].
Culture samples should ideally be transferred to the
Microbiology Department within 30 minutes of collec-
tion to avoid a delay in processing and bacterial over-
growth [73,74]. Storing LRT specimens refrigerated or
frozen for 24 hours is an acceptable alternative when
culturing cannot be performed immediately [75-77].
Despite this possibility, we would warn against this prac-
tice since any delay in receiving information will have
devastating clinical consequences.
Laboratory processing of samples upon arrival. Gram stain
There is still much controversy over the value of the
Gram stain for anticipating the microbiological diagnosis
of VAP. The medical literature is replete with varying data
on the sensitivity (57-95%), specificity (48-87%), positive
predictive value (PPV) (47-78%), negative predictive value
(NPV) (69-96%) and accuracy (60-88%) of the Gram stain
in the management of patients with VAP [78-82].
Some authors claim that a negative endotracheal aspir-
ate (EA) Gram stain is of great negative predictive value
for the diagnosis of VAP and may guide the decision to
not initiate or to limit antibiotic treatment until culture
results become available [78,80,83,84]. Our opinion is
that immediate reporting to the responsible clinicians of
the result of a Gram stain on LRT secretions obtained by
tracheal aspiration may help guide early treatment. At
our Microbiology Department, the diagnostic validity of
the Gram technique on EA in patients with suspected
VAP has been estimated at: sensitivity 91%, specificity
61%, PPV 50.5%, NPV 94%, test accuracy 70%, positive
likelihood ratio (PLR) 2.3, negative likelihood ratio (NLR)
0.14, and a post-test probability of a negative result of 6%
[85]. This means that a negative Gram stain makes it
highly unlikely that a positive culture result will be ob-
tained the next day.
As a complement to the Gram stain, quantifying the
proportion of cells containing intracellular organisms
has also been proposed as a rapid method for the diag-
nosis of VAP. A cut-off of >1-2% of “infected” cells in
bronchoalveolar lavage (BAL) specimens rendered a sen-
sitivity of 79–93.6% and a specificity of 82-100% [86-88].
Thus, the detection of intracellular organisms in BAL
specimens can be described as a rapid specific test with
a high positive predictive value, and is recommended by
the British Society of Antimicrobial Chemotherapy to
guide initial therapy (grade A recommendation) [89]. In
addition, this test does not seem to be affected by anti-
biotic therapy given up to 72 hours prior to sampling
[90]. Along these lines, the European care bundle for the
management of VAP recommends immediate reporting
of Gram stain findings in respiratory secretions, includ-
ing “infected” cells [91].
The guidelines of the Society for Healthcare and Epi-
demiology of America (SHEA) and the Infectious Dis-
eases Society of America (IDSA) published in 2008
recommend a Gram stain directly on the sample and the
quantitative culture of an EA or a BAL sample [92].
Are there any other rapid direct methods that provide
useful information before culture results become available?
Although it is widely accepted that the prognosis for a
patient with VAP depends on the antibiotic susceptibility
of the causative pathogen and on the time elapsed since
its diagnosis and the first dose of effective antibiotic re-
ceived [65,93], there is presently no rapid procedure
other than those mentioned whose efficacy in the man-
agement of VAP has been reliably proven. In the specific
field of VAP, there is a clear need to address new mo-
lecular techniques that can detect one or several micro-
organisms [94] or rapidly identify certain resistance
mechanisms directly on clinical samples. We recently
obtained excellent results for the rapid diagnosis of VAP
due to methicillin-resistant or susceptible Staphylococcus
aureus (MRSA, MSSA) by directly subjecting clinical
samples to PCR (GeneXpert, Cepheid® Inc., Sunnyvale,
CA) [95]. This simple procedure shows a high diagnostic
efficiency and can shorten the time to adequate anti-
biotic treatment. These results have also been validated
by other authors [96,97]. However, the GeneXpert kit
has not yet received CE mark approval for this purpose.
The ideal VAP molecular diagnostic assay should target
various microorganisms and resistance genes, including
S. aureus, Pseudomonas aeruginosa, Acinetobacter bau-
mannii, a DNA sequence common to all Enterobacteria-
ceae, and the resistance genes mecA, blaKPC, blaIMP, blaVIM
and blaOXA [98].
Rapid preliminary cultures and susceptibility testing
(VAP E-test)
Conventional processing of a secretion sample for micro-
biological investigation usually takes from 2 to 4 days.
After inoculation and incubation for 24–48 hours, bacter-
ial counts are performed and strains are isolated for pure
culture. This is followed by pathogen identification and
AST, which delays the results at least a further 24 hours.
To this process, we would need to add the time of delays
in transmitting information and in making therapeutic
decisions.
In a study conducted at the Hospital Gregorio Marañón
(Madrid, Spain), we compared the results of a direct E-test
antibiogram for 6 antibiotic agents conducted on clinical
LRT samples to those obtained by the standard AST. The
E-test antimicrobial susceptibility procedure is a quantita-
tive method for AST that consists of a plastic strip with a
predefined gradient of antibiotic. The stable gradient pro-
vides inoculum tolerance where a 100-fold variation in
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cfu/mL has minimal effect on the minimum inhibitory
concentration (MIC) of susceptible strains, and allows its
application directly to clinical specimens [99]. The six an-
tibiotics we used were oxacilin, cefepime, imipenem,
piperacillin-tazobactam, amikacin and ciprofloxacin. Sus-
ceptibility data, obtained in 18 to 24 hours, were found to
concur with those of the standard procedure at 48 to
72 hours in 98% of cases [100]. In a subsequent study, we
confirmed the more effective and reduced use of antibi-
otics in VAP patients associated with the use of this quick
procedure [101].
A new approach recently developed at our hospital is
a modification of the direct E-test technique using a
prototype chromogenic agar medium (Mueller-Hinton
base) to generate both rapid antibiotic susceptibility and
organism identification results [102,103]. In a preliminary
investigation of 143 LRT samples, 92.7% of the isolates
were rapidly identified in this medium after 18 hours and
100% after 24 hours of incubation. Full agreement with
the standard procedure was observed in 94.9% (Cercenado
et al., unpublished data). Although these data are prelim-
inary, we consider the use of chromogenic agar medium
for E-tests on LRT samples is an improvement over the
use of conventional Mueller-Hinton agar.
Other diagnostic markers of VAP
The use of biomarkers such as CRP to more objectively
and specifically diagnose VAP has also been assessed.
Lisboa et al. used CRP as a diagnostic and prognostic
marker, as well as to assess antibiotic treatment appro-
priateness [104]. These authors noted that the CRP coef-
ficient (defined as the ratio between CRP levels on
follow-up and CRP levels at baseline) decreased in pa-
tients receiving adequate treatment and that a coefficient
of 0.8 at 96 hours post treatment onset was a good indi-
cator of the appropriateness of antibiotic treatment (Se
77%, Sp 87%, area under the ROC curve 86%, 95% CI
75-96%). Unfortunately, CRP is a nonspecific biomarker
of inflammation and may also be elevated in the presence
of pulmonary infiltrates of non-infectious cause [74].
Regarding PCT, it is not a good marker for the diagno-
sis of VAP [105]. However, in VAP, this marker has been
described as prognostic with elevated levels indicating a
more severe clinical course and sustained high levels
during the first week of illness indicating a worse out-
come [106]. Some studies have also correlated a drop in
PCT with a favorable outcome [107,108] and reduced
antibiotic consumption [109], although in other studies,
neither PCT threshold values nor their kinetics were
able to predict VAP survival [110,111].
Despite these discrepancies, PCT seems to be a good
indicator of bacterial load in patients with VAP. Most
importantly, a low level of PCT is thought to accurately
reflect controlled bacterial infection [74].
Other proposed biomarkers are the soluble triggering
receptor expressed on myeloid cells-1 (Strem-1) [112]
and interleukin-1beta and interleukin-8 in BAL fluid
[113]. Chastre et al. recommend that PCT and Strem-1
should only be used to complement standard microbio-
logical diagnostic tests. However, knowledge of serum
PCT and Strem-1 levels may prompt a change in treat-
ment early in the course of VAP and such findings have
been used to step-up treatment when levels remain high
or to avoid long courses of antibiotics when the levels of
these markers rapidly fall [114]. Whether PCT and/or
Strem-1 guidance can reduce antibiotic use in such a
setting is yet to be seen, but the strategy appears promis-
ing [112,115].
The rapid diagnosis of urinary tract infection
The turnaround time for microbiological confirmation
of a urinary tract infection (UTI) in a urine culture is
not usually as critical as in life-threatening diseases like
sepsis. Still, microbiological confirmation of a UTI takes
24–48 hours. In the meantime, patients are usually given
empirical antibiotics, sometimes inappropriately.
Rapid UTI screening methods. The Gram stain
The usefulness of Gram staining of fresh uncentrifuged
urine to detect significant bacteriuria was first demon-
strated in 1968 [116], and it has since been used as a
screening test for UTI [117-119]. The accuracy of Gram
staining for the diagnosis of UTI has been reported in
the literature as: sensitivity 82.2-97.9%; specificity 66.0-
95.0%; PPV 31.6-94.3%, and NPV 95.2-99.5%, varying
with the different counts of microorganisms in the sam-
ple [118-122]. As with other rapid screening tests, accur-
acy is higher for greater bacterial counts.
The benefits of direct Gram staining of urine samples
sent for culture are clear: it shortens the turnaround
time for reporting negative culture results and guides
empirical antibiotic treatment when microorganisms are
seen. In addition, when compared to alternative rapid
screening tests, the Gram stain has a higher accuracy
[119,123] and lower cost [122].
The use of the Gram stain has not been generalized
because it needs more equipment and time than dipstick
analysis, and is unlikely to replace dipstick testing across
all health-care settings [123]. Skilled laboratory personnel
are needed to correctly evaluate smears [124]. Yet, in la-
boratories where stained smears are part of the routine
microbiological examination of urine samples, the time
necessary to perform the stain and examine the slide
under the microscope is relatively short [124].
MALDI-TOF mass spectrometry has been successfully
used to rapidly identify culture-isolated microorganisms
[42,43] but has been little used directly on clinical
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samples except positive blood cultures and urine sam-
ples [48,125-128].
We recently assessed the capacity of subjecting urine
samples to sequential Gram staining and MALDI-TOF
MS to anticipate clinically useful information [129].
From May through June 2012, 1,000 random urine sam-
ples from patients with a suspected UTI were Gram
stained, and those returning bacteria of a single morpho-
type were subjected to MALDI-TOF MS. This procedure
was correlated with standard semiquantitative urine
culture results and the outcomes recorded as: match (in-
formation anticipative of culture result), minor error
(information partially anticipative of culture result), or
major error (information incorrect and potentially lead-
ing to inappropriate antibiotic therapy decisions). Results
were available in 1 hour. Information anticipative of cul-
ture results was provided in 83% of cases, information
with minor errors in 13% and information with major
errors in 4%. For 96% of urine samples from patients
with suspected UTI, the sequential procedure provided
information that was consistent or showed minor errors.
In future work, the clinical impacts of this rapid UTI
diagnosis strategy need to be assessed in terms of factors
such as a reduced time to appropriate empirical treat-
ment or earlier withdrawal of unnecessary antibiotics.
Anticipation of antibiotic susceptibility with direct testing
The practice of performing direct AST of urine speci-
mens has the advantage of next-day reporting of anti-
microbial susceptibilities. Direct AST of urine samples
has proved to be as effective as standard methods, pro-
viding results 24 hours in advance with similar costs
[130]. However, this method is criticized because the in-
oculum is not standardized and because sometimes a
mixture of microorganisms can be found in the sample.
Nevertheless, it has been used for many years with excel-
lent results [131-136] and correlates well with reference
methods. The fact that this method can confirm the ap-
propriate antibiotic treatment in only 24 hours translates
to the reduced use of wide-spectrum antibiotics with the
consequence of diminishing antibiotic resistance.
Rapid diagnosis of skin and soft tissue infections
According to the IDSA 2013 guide to the diagnosis of
infectious diseases [137], cultures are not indicated for
uncomplicated common forms of skin and soft tissue in-
fections (SSTIs) (e.g., cellulitis, subcutaneous abscesses)
treated in the outpatient setting. Whether cultures are
beneficial for managing cellulitis in the hospitalized pa-
tient is uncertain and the sensitivity of blood cultures in
this setting is low. Cultures are however recommended
for the patient who requires operative incision and
drainage because of the risk of deep structure and under-
lying tissue involvement [138]. The IDSA guide includes
recommendations for sampling and processing specimens
for a microbiological diagnosis of the most frequent
SSTIs. Basically, the quality of the sample and the number
of potential pathogens to be considered is first established
in a Gram stain, and this is followed by a conventional
culture procedure. These still traditional procedures are
not rapid.
The recent availability of a rapid-detection assay to
identify MRSA from wound specimens allows for better-
informed therapeutic decisions. The Xpert MRSA/SA
skin and soft tissue infection assay (GeneXpert, Cepheid®
Inc., Sunnyvale, CA) is approved for rapid detection
(within 1 h) of MRSA and MSSA in wounds. In a multi-
center evaluation that included a total of 114 wound
specimens, the MRSA/SA SSTI assay showed a Se of
97%, a Sp of 96%, a PPV of 92% and a NPV of 99% for
MRSA detection; similar percentages were noted for
MSSA [139]. Overall agreement between the assay and
standard culture was 96.5%.
The GeneXpert kit directly applied to synovial fluid
and tissue specimens (e.g., bone, muscle, fascia, etc.) has
also proved useful for the diagnosis of osteoarticular and
chronic prosthetic joint infections due to staphylococci
[140,141], though it has not yet received CE mark ap-
proval for this purpose.
The rapid identification and differentiation of MRSA
in a wound specimen allows clinicians to more rapidly
initiate appropriate antimicrobial therapy.
The steps recommended for the early diagnosis of a
SSTI by Streptococcus pyogenes are: direct Gram staining
of skin biopsies, tissues, fascia, muscle, purulent exudate
or joint aspirates and the rapid detection of capsule and
protein antigens in skin and/or tissues using available
kits that show a Se of 60% to 91% and a Sp of 85% to
98% [142-144].
Other rapid microbiological tests that may provide useful
information in ICU patients
Besides the tests already mentioned, other diagnostic
tests used in Microbiology can expedite the diagnosis of
infection in these patients.
Those most often used in clinical practice, which also
show adequate diagnostic performance, are the detection
of the antigens of Streptococcus pneumoniae [145] and
Legionella pneumophila serogroup 1 in urine [146] for
patients with pneumonia; the detection of some viruses
such as influenza and other respiratory viruses, or en-
terovirus and other central nervous system viruses [147];
and the detection of Mycobacterium tuberculosis, which
in some cases is accompanied by the identification of re-
sistance genes [148]. The detection of respiratory viral
agents includes single or multiple pathogens (multiplex
panels), which is highly convenient since most of these
agents cause similar symptoms.
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Conclusions
Much progress has been recently made in the rapid etio-
logic diagnosis of infectious diseases. Some of the new ap-
proaches available are even able to detect antimicrobial
resistances and this allows for treatment optimization, es-
pecially in the most vulnerable patients such as those ad-
mitted to the ICU. Current microbiology has shortened
turnaround times in the treatment of many types of infec-
tion, such as sepsis, pneumonia, urinary tract infections,
skin and soft tissue infections, viral infections or tubercu-
losis. Molecular techniques still have issues that need to be
dealt with such as their limits of detection and sensitivity
for certain samples and certain situations, their correlation
with adequate diagnostic gold standards, their clinical val-
idation and the correct interpretation of results, and the
risk of contamination. Improvements are also needed in
terms of widening the spectrum of pathogens and resist-
ance mechanisms that may be identified or the sample
types these procedures can be used on. Despite these limi-
tations, the future of the field of molecular techniques for
the rapid diagnosis of infections is highly promising.
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